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activityAbstract In the present study novel derivatives of 4-thiazolidinone were prepared from biphenyl-4-
carboxylic acid and evaluated for their in vitro antimicrobial activity against two Gram negative
strains (Escherichia coli and Pseudomonas aeruginosa) and two Gram positive strains (Bacillus sub-
tilis and Staphylococcus aureus) and fungal strain Candida albicans and Aspergillus niger. The newly
synthesized compounds were characterized by IR, 1H NMR and C, H, N analyses. The results
revealed that all synthesized compounds have a signiﬁcant biological activity against the tested
microorganisms. Among the synthesized derivatives 4g (biphenyl-4-carboxylic acid [2-(3-bromophe-
nyl)-5-(3-nitrobenzylidene)-4-oxo-thiazolidin-3-yl]-amide) and 4i (biphenyl-4-carboxylic acid [5-(3-
bromobenzylidene)-2-(3-bromophenyl)-4-oxo-thiazolidin-3-yl]-amide) were found to be most effec-
tive antimicrobial compounds.
ª 2010 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Microbial resistance to antimicrobial agents is of grave
concern in the medical community. Hence, the development
of novel, potent, and unique antimicrobial agents are the pre-
eminent way to overcome microbial resistance and develop
effective therapies. 4-Thiazolidinone and its derivatives have
attracted considerable attention for the past few decades due
to their chemotherapeutical values (Verma and Saraf, 2008).
Table 1 Physical data of 2,5-disubstituted-4-thiazolidinones.
Compound Ar Ar0 Molecular formula Molecular weight Melting point (C) Yield (%) Rf value
4a C6H5 C6H5 C29H22N2O2S 462.56 214–216 71.32 0.63
4b C6H5 3-NO2C6H4 C29H21N3O4S 507.56 217–219 78.14 0.71
4c C6H5 4-ClC6H4 C29H21ClN2O2S 497.01 223–224 82.26 0.59
4d C6H5 3-BrC6H4 C29H21BrN2O2S 541.46 216–217 79.40 0.62
4e C6H5 4-OCH3C6H4 C30H24N2O3S 492.59 210–212 81.60 0.68
4f 3-BrC6H4 C6H5 C29H21BrN2O2S 541.46 228–230 78.46 0.92
4g 3-BrC6H4 3-NO2C6H4 C29H20BrN3O4S 586.46 238–239 78.40 0.88
4h 3-BrC6H4 4-ClC6H4 C29H20BrClN2O2S 575.90 225–227 81.20 0.79
4i 3-BrC6H4 3-BrC6H4 C29H20Br2N2O2S 620.35 245–248 78.62 0.82
4j 3-BrC6H4 4-OCH3C6H4 C30H23BrN2O3S 571.48 234–235 81.80 0.73
4k 4-FC6H4 C6H5 C29H21FN2O2S 480.55 242–243 79.34 0.78
4l 4-FC6H4 3-NO2C6H4 C29H20FN3O4S 525.55 235–237 78.86 0.84
For mobile phase: chloroform:benzene:glacial acetic acid (3:1:1, v/v/v).
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pharmacological actions such as antimicrobial (Bondock
et al., 2007; Shah and Desai, 2007; Samir et al., 2007; Vicini
et al., 2006; Sharma et al., 2006; Handan et al., 2005), analgesic
(Knutsen et al., 2007), anti-inﬂammatory (Ottana et al., 2005;
Goel et al., 1999), anti-HIV (Balzarini et al., 2007), cytotoxic
(Mujeebur et al., 2005), and anticonvulsant (Gursoy and Ter-
zioglu, 2005) activities. Also, 4-thiazolidinones have been
found as novel inhibitors of bacterial enzyme MurB, a key en-
zyme responsible for the synthesis of peptidoglycon (Andres
et al., 2000).
Inspired by the above facts and in continuation of our
ongoing research program in the ﬁeld of synthesis and antimi-
crobial activity of medicinally important compounds (Deep
et al., 2010b; Madhukar et al., 2009; Kumar et al., 2010), we
hereby report the synthesis and antimicrobial activity of 4-
thiazolidinone derivatives. All these compounds have been re-
ported with their anti-inﬂammatory activity elsewhere (Deep
et al., 2010a). The structures of all compounds have been con-
ﬁrmed by elemental and spectral analysis (IR and 1H NMR).Scheme 1 Preparation of biphenyl-4-carboxylic acid-5-(arylid-
ene)-2-(aryl)-4-oxo-thiazolidin-3-yl-amides (4a–l).2. Experimental
The purity of the synthesized compounds were ascertained by
thin layer chromatography on silica gel G in various solvent
systems using iodine vapours as detecting agent. Melting
points were determined by the melting point determination
apparatus (TEMPO) in open capillary tubes and are uncor-
rected. Elemental analyses were done using Carlo Erba 1106
CHN Analyzer. Infra-red spectra were recorded on Perkin El-
mer Spectrum RXI FTIR spectrophotomer in KBr phase. Pro-
ton NMR spectra were recorded on Bruker Avance II 400
NMR Ultra Shield Spectrometer using DMSO-d6 as a solvent
and tetramethyl silane as internal standard. Chemical shift va-
lue is expressed in delta parts per million (d ppm). All the com-
pounds have been screened in vivo for their anti-inﬂammatory
activity.
2.1. Chemistry
A series of biphenyl-4-carboxylic acid-5-(arylidene)-2-(aryl)-4-
oxothiazolidin-3-yl-amides has been synthesized. Reaction of
acid hydrazide (1) with aromatic aldehydes yielded the corre-sponding hydrazones (2a–c) which on further reaction with
thioglycolic acid in methanol afforded the corresponding 2-
substituted-4-thiazolidinones (3a–c). The compounds (3a–c)
were further reacted with aromatic aldehydes in presence of
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thiazolidinones (4a–l). The synthesized 2,5-disubstituted-4-
thiazolidinones were characterized on the basis of the spectral
and analytical studies.2.2. General method
The title compounds were prepared in following steps:
2.2.1. Synthesis of hydrazone (2)
A mixture of biphenyl-4-carboxylic acid hydrazide (0.025 mol,
5.3 g) and required aromatic aldehydes (0.025 mol) was re-
ﬂuxed in methanol (50 ml) in the presence of a catalytic
amount of glacial acetic acid for about 2 h. The mixture was
cooled and the solid obtained was separated by ﬁltration and
recrystallized from methanol to give the corresponding
hydrazones.
2.2.2. Synthesis of 2-substituted-4-thiazolidinone (3a–c)
A mixture of appropriate Schiff’s base (0.015 mol) (2) and re-
quired amount of thioglycolic acid (0.015 mol, 1.40 ml) in
N,N-dimethylformamide (DMF) (50 ml), containing a pinch
of anhydrous ZnCl2 was reﬂuxed for about 6 h. The reaction
mixture was cooled and poured on to crushed ice. The solid
thus obtained was ﬁltered, washed with water and the product
was recrystallized from rectiﬁed spirit.
2.2.3. Synthesis of 2,5-disubstituted-4-thiazolidinone (4a–l)
A suspension of 2-substituted-4-thiazolidinone (0.01 mol), re-
quired aromatic aldehydes (0.01 mol) and anhydrous sodium
acetate was prepared in glacial acetic acid and reﬂuxed for
5–7 h. After cooling, the solution was poured on crushed ice
to precipitate the product. The product was recrystallized from
ethanol.
By adopting similar type of procedures, and employing
equimolar quantities of reactants, 12 compounds were synthe-
sized. Physical and analytical data of synthesized compounds
is given in Table 1. Synthetic pathway for preparation of title
compounds is shown in Scheme 1.2.3. Spectral data
2.3.1. Biphenyl-4-carboxylic acid (5-benzylidene-4-oxo-2-
phenylthiazolidin-3yl)-amide (4a)
IR (KBr, cm1): 3198 (N–H), 3028–2923 (C–H), 1634–1657
(C‚O), 1605–1483 (C‚C), 1446–1402 (C–N). 1H NMR
(300 MHz, DMSO-d6, d ppm): 8.43–7.38 (m, 9H, Ar H),
8.06 (s, 1H, –NH), 7.68–7.50 (m, 5H, Ar0 H), 7.48–7.40 (m,
4H, Ar H), 7.32 (s, 1H, C‚CH), 4.62 (s, 1H, –NCHS). Anal.
Calcd. for C29H22N2O2S: C, 75.30; H, 4.79; N, 6.06. Found C,
75.26; H, 4.81; N, 6.01.
2.3.2. Biphenyl-4-carboxylic acid [5-(3-nitrobenzylidene)-4-
oxo-2-phenylthiazolidin-3-yl]-amide (4b)
IR (KBr, cm1): 3253 (N–H), 3052 (C–H), 1657 (C‚O),
1608–1485 (C‚C), 1448–1435 (C–N), 1529–1581 (N–O). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.60–7.79 (m, 4H, Ar0
H), 8.05 (s, 1H, –NH), 7.78–7.47 (m 9H, Ar, H), 7.51–7.42
(m, 5H, Ar H), 7.40 (s, 1H, C‚CH), 3.34 (s, 1H, –NCHS).Anal. Calcd. for C29H21N3O4S: C, 68.62; H, 4.17; N, 8.28.
Found C, 68.66; H, 4.21; N, 8.22.
2.3.3. Biphenyl-4-carboxylic acid [5-(4-chlorobenzylidene)-4-
oxo-2-phenylthiazolidin-3-yl]-amide (4c)
IR (KBr, cm1): 3403 (N–H), 2933 (C–H), 1716–1681 (C‚O),
1606–1485 (C‚C), 1436–1422 (C–N), 749–698 (C–Cl). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.49–7.77 (m, 9H, Ar
H), 8.04 (s, 1H, –NH), 7.47–7.40 (m, 5H, Ar H), 7.67–7.50
(m, 4H, Ar H), 7.41 (s, 1H, C‚CH), 3.92 (s, 1H, –NCHS).
Anal. Calcd. for C29H21ClN2O2S: C, 70.08; H, 4.26; N, 5.64.
Found C, 70.02; H, 4.30; N, 5.66.
2.3.4. Biphenyl-4-carboxylic acid [5-(3-bromobenzylidene)-4-
oxo-2-phenylthiazolidin-3-yl]-amide (4d)
IR (KBr, cm1): 2993–2944 (C–H), 1717–1682 (C‚O), 1605–
1485 (C‚C), 1436–1422 (C–N), 545 (C–Br). 1H NMR
(300 MHz, DMSO-d6, d ppm): 8.47–7.73 (m, 9H, Ar H),
8.07 (s, 1H, –NH), 7.46–7.42 (m, 5H, Ar H), 7.69–7.48 (m,
4H, Ar H), 7.38 (s, 1H, C‚CH), 4.24 (s, 1H, –NCHS). Anal.
Calcd. for C29H21BrN2O2S: C, 64.33; H, 3.91; N, 5.71. Found
C, 64.29; H, 3.96; N, 5.70.
2.3.5. Biphenyl-4-carboxylic acid [5-(4-methoxybenzylidene)-4-
oxo-2-phenylthiazolidin-3-yl]-amide (4e)
IR (KBr, cm1): 3269 (N–H), 3030–2927 (C–H), 1650 (C‚O),
1607–1485 (C‚C), 1447–1419 (C–N), 1253 (C–O–C). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.41–7.46 (m, 9H, Ar
H), 8.03 (s, 1H, –NH), 7.40–7.22 (m, 4H, Ar0 H), 7.42 (s,
1H, C‚CH), 7.38–7.26 (m, 5H, Ar0 H), 5.18 (s, 1H, –NCHS),
3.52 (s, 1H, –OCH). Anal. Calcd. for C30H24N2O3S: C, 73.13;
H, 4.91; N, 5.69. Found C, 73.11; H, 4.95; N, 5.72.
2.3.6. Biphenyl-4-carboxylic acid [5-benzylidene-2-(3-
bromophenyl)-4-oxothiazolidin-3-yl]-amide (4f)
IR (KBr, cm1): 3209 (N–H), 3030 (C–H), 1649 (C‚O),
1606–1484 (C‚C), 1447–1403 (C–N), 554–506 (C–Br). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.48–7.40 (m, 9H, Ar
H), 8.04 (s, 1H, –NH), 7.68–7.38 (m, 5H, Ar0 H), 7.48–7.28
(m, 4H, Ar H), 7.46 (s, 1H, C‚CH), 3.09 (s, 1H, –NCHS).
Anal. Calcd. for C29H21BrN2O2S: C, 64.33; H, 3.91; N, 5.17.
Found C, 64.31; H, 3.96; N, 5.14.
2.3.7. Biphenyl-4-carboxylic acid [2-(3-bromophenyl)-5-(3-
nitrobenzylidene)-4-oxo-thiazolidin-3-yl]-amide (4g)
IR (KBr, cm1): 3261 (N–H), 3034 (C–H), 1655 (C‚O), 1528
(N–O), 1608–1483 (C‚C), 1445–1402 (C–N), 509 (C–Br). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.84–7.45 (m, 4H, Ar0
H), 8.06–7.37 (m, 9H, Ar H), 8.00 (s, 1H, –NH), 7.54–7.32
(m, 4H, Ar H), 7.50 (s, 1H, C‚CH), 4.59 (s, 1H, –NCHS).
Anal. Calcd. for C29H20BrN3O4S: C, 59.39; H, 3.44; N, 7.17.
Found C, 59.43; H, 3.47; N, 7.21.
2.3.8. Biphenyl-4-carboxylic acid [2-(3-bromophenyl)-5-(4-
chlorobenzylidene)-4-oxo-thiazolidin-3-yl]-amide (4h)
IR (KBr, cm1): 3282 (N–H), 3036 (C–H), 1651 (C‚O),
1607–1447 (C‚C), 1447 (C–N), 780–603 (C–Cl), 513 (C–Br).
1H NMR (300 MHz, DMSO-d6, d ppm): 8.45–7.48 (m, 9H,
Ar H), 8.00 (s, 1H, –NH), 7.58 (s, 1H, C‚CH), 7.52–7.46
(m 4H, Ar0 H), 7.50–7.28 (m, 4H, Ar H), 3.02 (s, 1H, –NCHS).
Table 2 In vitro antibacterial activity of the title compounds (4a–l).
Compound Minimum inhibitory concentration (lg ml1)
E. coli (MTCC 40) P. aeruginosa (MTCC 2453) S. aureus (MTCC 121) B. subtilis (MTCC 96)
4a 6.25 6.25 6.25 3.12
4b 6.25 3.12 3.12 1.56
4c 3.12 12.5 3.12 6.25
4d 12.5 6.25 3.12 6.25
4e 6.25 6.25 6.25 1.56
4f 6.25 3.12 3.12 3.12
4g 3.12 1.56 1.56 1.56
4h 12.5 6.25 6.25 6.25
4i 6.25 6.25 3.12 3.12
4j 1.56 12.5 3.12 1.56
4k 6.25 12.5 6.25 3.12
4l 12.5 3.12 6.25 6.25
Ciproﬂoxacin (standard drug) 0.01 0.25 0.15 0.12
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Found C, 60.43; H, 3.54; N, 4.83.Table 3 In vitro antifungal activity of the title compounds
(4a–l).
Compound Minimum inhibitory concentration (lg ml1)
C. albicans
(MTCC 8184)
A. niger
(MTCC 8189)
4a 3.12 6.25
4b 3.12 1.56
4c 1.56 3.12
4d 3.12 6.25
4e 3.12 1.56
4f 3.12 6.25
4g 1.56 3.12
4h 6.25 3.12
4i 1.56 1.56
4j 6.25 3.12
4k 6.25 12.5
4l 6.25 6.25
Clotrimazole
(standard drug)
0.10 0.302.3.9. Biphenyl-4-carboxylic acid [5-(3-bromobenzylidene)-2-
(3-bromophenyl)-4-oxo-thiazolidin-3-yl]-amide (4i)
IR (KBr, cm1): 3428 (N–H), 3044 (C–H), 1650 (C‚O),
1607–1484 (C‚C), 1447–1406 (C–N), 554–503 (C–Br). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.41–7.42 (m, 9H, Ar
H), 8.03 (s, 1H, –NH), 7.62–7.30 (m, 4H, Ar0 H), 7.51 (s,
1H, C‚CH), 7.46–7.26 (m, 4H, Ar0 H). Anal. Calcd. for
C29H20Br2N2O2S: C, 56.15; H, 3.25; N, 4.52. Found C,
56.20; H, 3.23; N, 4.57.
2.3.10. Biphenyl-4-carboxylic acid [2-(3-bromophenyl)-5-(4-
methoxybenzylidene)-4-oxo-thiazolidin-3-yl]-amide (4j)
IR (KBr, cm1): 3428 (N–H), 3034 (C–H), 1650 (C‚O),
1606–1473 (C‚C), 1447–1403 (C–N), 1280–1253 (C–O–C),
553–531 (C–Br). 1H NMR (300 MHz, DMSO-d6, d ppm):
8.05–7.44 (m, 9H, Ar H), 8.02 (s, 1H, –NH), 7.46–7.26 (m,
4H, Ar H), 7.41 (s, 1H, C‚CH), 7.39–6.93 (m, 4H, Ar0 H),
4.60 (s, 1H, –NCHS), 3.48 (s, 1H, –OCH). Anal. Calcd. for
C30H23BrN2O3S: C, 63.05; H, 4.06; N, 4.90. Found C, 63.01;
H, 4.08; N, 4.86.
2.3.11. Biphenyl-4-carboxylic acid [5-benzylidene-2-(4-
ﬂuorophenyl)-4-oxothiazolidin-3-yl]-amide (4k)
IR (KBr, cm1): 3211 (N–H), 3038 (C–H), 1657 (C‚O),
1606–1475 (C‚C), 1445–1401 (C–N), 1233 (C–F). 1H NMR
(300 MHz, DMSO-d6, d ppm): 8.22–7.47 (m, 9H, Ar H),
8.03 (s, 1H, –NH), 7.56–7.37 (m, 5H, Ar0 H), 7.34–7.12 (m,
4H, Ar H), 7.52 (s, 1H, C‚CH), 3.58 (s, 1H, –NCHS). Anal.
Calcd. for C29H21FN2O2S: C, 72.48; H, 4.40; N, 5.83. Found
C, 72.45; H, 4.37; N, 5.85.
2.3.12. Biphenyl-4-carboxylic acid [2-(4-ﬂuorophenyl)-5-(3-
nitrobenzylidene)-4-oxo-thiazolidin-3-yl]-amide (4l)
IR (KBr, cm1): 3245 (N–H), 3033 (C–H), 1651 (C‚O), 1522
(N–O), 1605–1483 (C‚C), 1445–1402 (C–N), 1226 (C–F). 1H
NMR (300 MHz, DMSO-d6, d ppm): 8.77–7.48 (m, 4H, Ar0
H), 8.11–7.35 (m, 9H, Ar H), 8.01 (s, 1H, –NH), 7.57–7.35
(4H, Ar H), 7.49 (s, 1H, C‚CH), 4.31 (s, 1H, –NCHS). Anal.Calcd. for C29H20FN3O4S: C, 66.28; H, 3.84; N, 8.00. Found
C, 66.25; H, 3.80; N, 6.03.
3. Antimicrobial evaluation
The synthesized compounds were evaluated for their in vitro
antimicrobial activity against Gram positive bacteria: Staphy-
lococcus aureus (MTCC 121), Bacillus subtilis (MTCC 96),
Gram negative Escherichia coli (MTCC 40), Pseudomonas
aeruginosa (MTCC 2453) and fungal strain: Candida albicans
(MTCC 8184) and Aspergillus niger (MTCC 8189). Antimicro-
bial activity was assessed by serial two-fold dilution technique.
Ciproﬂoxacin was used as a standard drug for antibacterial
activity and clotrimazole was used as a standard drug for anti-
fungal activity. All the compounds were dissolved in dimethyl
sulfoxide to give a concentration of 10 lg ml1. Twofold dilu-
tions of test and standard compounds were prepared in double
strength nutrient broth I.P. (bacteria) or Sabouraud dextrose
broth I.P. (Pharmacopoeia, 1996) (fungi). The stock solution
was serially diluted to give concentrations of 25–0.78 lg ml1
in nutrient broth. The inoculum size was approximately
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at 37 ± 1 C for 24 h (bacteria) and 25 C for 7 days (A. niger).
After that, the inoculated culture tubes were macroscopically
examined for turbidity. The culture tube showing turbidity
(lower concentration) and the culture tube showing no turbid-
ity (higher concentration) gave the minimum inhibitory con-
centration (MIC) for the compound. The MIC for
antibacterial is given in Table 2 and MIC for antifungal is gi-
ven in Table 3.
4. Results and discussion
In this study 12 novel compounds incorporating the scaffold of
thiazolidinone have been synthesized and evaluated for antimi-
crobial activity. We described here a convenient approach to
the preparation of biphenyl-4-carboxylic acid-5-(arylidene)-2-
(aryl)-4-thiazolidinone. All compounds were synthesized
according to Scheme 1. At the ﬁrst stage, Schiff’s bases of
biphenyl-4-carboxylic acid hydrazide and aromatic aldehydes
were prepared. Further, reaction of these Schiff’s bases with
thioglycollic acid in DMF and in presence of a small amount
of ZnCl2 yield the 2-substituted-4-thiazolidinone. 2-Substi-
tuted-4-thiazolidinone was reacted with aromatic aldehydes
in the presence of sodium acetate and glacial acetic acid to
yield the 2,5-disubstituted-4-thiazolidinone. Data obtained
were found to be in good agreement with the calculated values
of the proposed structure. All the synthesized compounds (4a–
l) showed signiﬁcant antimicrobial activity, against bacterial
strain, E. coli (MIC 12.5–1.56 lg ml1), P. aeruginosa (MIC
12.5–1.56 lg ml1), S. aureus (MIC 6.25–1.56 lg ml1) and
B. subtilis (MIC 6.25–1.56 lg ml1) as compared to the stan-
dard drug ciproﬂoxacin and against fungal strain, C. albicans
(MIC 6.25–1.56 lg ml1) and A. niger (12.5–1.56 lg ml1) as
compared to the standard drug clotrimazole. Compound 4g
with its electron withdrawing group substitutions (bromo
and nitro group) on aromatic rings was the most active com-
pound against the bacterial strain. Compound 4i with their
bromo substitution on both the aromatic rings was the most
active compound against the fungal strain. More extensive
study is also warranted to determine additional physicochem-ical and biological parameters to have a deeper insight into
structure–activity relationship and to optimize the effective-
ness of this series of molecules.
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